Table I.
Characteristics of study population by group
| Group 1 Disease-Free n = 7 | Group 2 Response/Relapse n = 11 | Group 3 Stable Disease n = 10 | Group 4 Disease Progression n = 33 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | n | (%) | n | (%) | ||
| Gender | Male | 5 | (71.4) | 7 | (63.6) | 6 | (60.0) | 27 | (81.8) |
| Female | 2 | (28.6) | 4 | (36.4) | 4 | (40.0) | 6 | (18.2) | |
| Race | Caucasian | 7 | (100.0) | 8 | (72.7) | 8 | (80.0) | 29 | (87.8) |
| Hispanic | 0 | (0.0) | 3 | (27.3) | 1 | (10.0) | 2 | (6.1) | |
| Black | 0 | (0.0) | 0 | (0.0) | 1 | (10.0) | 2 | (6.1) | |
| Stage IV Age (yrs) | Median | 52 | 47 | 61.5 | 50 | ||||
| Range | 40–70 | 40–70 | 35–74 | 30–65 | |||||
| No. disease sites | 1 | 4 | (57.1) | 10 | (90.9) | 6 | (60.0) | 14 | (42.4) |
| 2 | 3 | (42.9) | 0 | (0.0) | 4 | (40.0) | 13 | (39.4) | |
| ≥3 | 0 | (0.0) | 1 | (9.1) | 0 | (0.0) | 6 | (18.2) | |
| Lung, lymph node only | yes | 4 | (57.1) | 8 | (72.7) | 3 | (30.0) | 15 | (45.5) |
| no | 3 | (42.9) | 3 | (27.3) | 7 | (70.0) | 18 | (54.5) | |
| Treatment | IFN alone | 3 | (42.9) | 3 | (27.3) | 7 | (70.0) | 2 | (6.1) |
| IL-2 alone | 0 | (0.0) | 0 | (0.0) | 0 | (8.3) | 2 | (6.1) | |
| IL-2 + IFN | 4 | (57.1) | 8 | (72.7) | 3 | (30.0) | 26 | (78.8) | |
| IL2 + TNF | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 3 | (9.0) | |
| Stage IV Surv (mos) | Median | 137 | 55 | 124 | 14.5 | ||||
| Range | 94+–167+ | 4–162+ | 62–184+ | 4–57 | |||||